Session: 506. Bone Marrow Microenvironment: Poster III
Methods: In this study, we established a 3-dimensional (3D) biomimetic model of decellularized Wharton’s jelly matrix and primary AML patient samples to simulate the bone marrow microenvironment and the interplay between AML cells, MSCs, and T cells. The MSCs were isolated and expanded from the bone marrow mononuclear cells of each AML patient (n=4) to be used for the 3D model development. The AML cells and PBMCs for each of the corresponding patient were seeded in the presence or absence of MSCs and incubated for 1 day to assess the level of AML killing and the level of T cell activation using a far red-labeled AML cell-based killing assay and flow cytometry of intracellular cytokines (IFNγ, TNFα), respectively. An identical experimental set up was incubated for 3 days for immunophenotypic characterization of the surface markers (AML cells: CD33, CD34, HLA-ABC, PD-L1; CD8+ T cells: CD3, CD4, CD8, PD-1, LAG-3, TIM-3) using flow cytometry. With the established 3D model, the effect of CPI (bispecific anti-PD-1 x anti-LAG-3 DART®molecule, MGD013/tebotelimab; anti-LAG-3 IgG4 antibody; and anti-PD-1 IgG4 antibody, nivolumab) on AML killing and T-cell activity were assessed and compared to a palivizumab-based IgG4 antibody as a control. The DART molecule and antibodies, except for nivolumab, were provided by MacroGenics, Inc., MD, USA.
Results: The patient-derived bone marrow MSCs were immunophenotypically characterized by flow cytometry to be ≥95% positive in CD73, CD90, and CD105 expression; and <2% positive in CD45 expression. Immunofluorescence confocal microscopy of the cryostat serial sectioned 3D matrix scaffolds showed the physical contacts and the potential co-localization between the three cell types within the 3D matrix scaffold. To identify the impact of the MSCs on CD8+ T cell killing of AML cells within the 3D model, we observed a lowered level of T cell-based AML killing (n=4; P=0.0273), accompanied with a lowered intracellular IFNγ and TNFα levels of CD8+ T cells (n=4; P=0.0288 and P=0.0433, respectively). A trend of higher exhaustion marker LAG-3 expression was also observed in the presence of MSCs (n=4; P=0.0602) with a statistically significant higher expression of TIM-3 (n=4; P=0.0416). Assessing the influence of MSCs on AML immune evasion, a trend of lowered MHC-I expression (n=4; P=0.0684) and a higher level of PD-L1 expression (n=4; P=0.0349) on AML cells was observed in the presence of MSCs. Comparing the effect of the immune CPI relative to the control antibody in reversing the MSC-mediated immunosuppression, the LAG-3 inhibitor-treated condition was shown to have a higher level of AML killing (n=4; P=0.0178), compared to nivolumab and MGD013 treatments. The elevated AML killing of the LAG-3 inhibitor treatment condition is accompanied with a higher level of intracellular IFNγ expression of CD8+ T cells (n=4; P=0.0141).
Conclusion: MSCs play a major role in influencing CD8+ T cell-mediated killing of AML cells through the suppression of CD8+ T cell activity, potentially involving the LAG-3 immune checkpoint mechanism. LAG-3 immune checkpoint inhibitor showed effective response in reversing T-cell suppression within the AML microenvironment and warrants further investigation as an immunotherapeutic in AML.
Disclosures: Lin: Aptevo; Bio-Path Holdings; Ciclomed; Cleave; Jazz; Jazz Pharmaceuticals; Leukemia & Lymphoma Society; Kura Oncology; Trovagene: Research Funding; Jazz Pharmaceuticals; Servier: Consultancy. McGuirk: CRISPR therapeutics: Consultancy; Envision: Consultancy; Sana technologies: Consultancy; Allo Vir: Consultancy; Autolus: Consultancy; NEKTAR therapeutics: Consultancy; Caribou bio: Consultancy; Novartis: Consultancy; Legend biotech: Consultancy; Kite: Consultancy; BMS: Consultancy. Godwin: Sinochips Diagnostics: Honoraria, Other: Co-founder; Leidos Biomedical Research, Inc.: Research Funding; Clara Biotech, Inc.: Research Funding; VITRAC Therapeutics: Research Funding; Biovica, Inc.: Honoraria; Predicine: Research Funding; DetectOn Diagnostics, Inc.: Consultancy; Exokeryx, Inc.: Consultancy; BioFluidica, Inc.: Research Funding; Amprion, LLC: Consultancy; Biological Dynamics, Inc.: Consultancy. Abdelhakim: Iovance Biotherapeutics: Research Funding.